Safety and Efficacy of Low Intensity Shockwave Therapy in Treating Diabetic Foot Ulcers

February 21, 2016 updated by: Hadassah Medical Organization

Low intensity shockwaves for treating diabetic foot ulcers (DFUs) have been in evaluation for the past 5 years. Many researchers showed the effectiveness of Low intensity shockwaves of in accelerating the healing rate of non-ischemic chronic DFUs. Wang et al. showed, the use of Low intensity shockwaves on DFUs, significantly improved topical blood flow perfusion rate, increased cell proliferation and cell activity and decreased cell apoptosis.

The present study deals with the effect of low intensity shockwaves on DFUs. Shockwave treatment will be done together with the standard conventional treatment for DFUs, compared to a control group who will receive the same conventional standard of care.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

30

Phase

  • Phase 2
  • Phase 1

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

  • Inclusion Criteria:

    1. Chronic non-healing diabetic foot ulcers for more than 2 months.
    2. Age 18-80 years
    3. Ankle Brachial Index (ABI) ≥0.6
    4. Diabetic Foot Ulcer with the long diameter of ≤7cm and a short diameter of ≥1cm
    5. The target ulcer is up to Wagner's grade 3
    6. Albumin level ≥25g/L
    7. Hemoglobin level ≥90g/L
    8. Estimated Glomerular Filtration Rate (eGFR) ≥30ml/min/1.73m2
    9. The patient agrees to comply with study protocol requirements, including the shockwave procedure, self-care of the ulcer (dressings, orthotics etc.) and all follow-up visit requirements

  • Exclusion Criteria:

    1. Pregnancy or lactation
    2. ABI <0.6
    3. The long diameter of the target ulcer is >7cm and the short diameter is <1cm
    4. The target ulcer is of Wagner's grade 4 or above
    5. Severe Hypoalbuminemia <25g/L
    6. Severe anemia, Hemoglobin level <90g/L
    7. eGFR <30ml/min/1.73m2
    8. Patients suffering from acute Charcot foot
    9. Severe edema of the treated limb
    10. Patient with present malignancy or past malignancy in the treated area
    11. Systemic chemotherapy/ radiation treatment within the last 6 months
    12. Deep vein thrombosis within the last 6 months

    13. Any other experimental treatment or participation in other studies

      -

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Extracorporeal Shockwave Therapy and debridement
The treatment will be performed as an outpatient care procedure with no anesthesia. Patients will undergo wound debridement and cleansing before each treatment. The transducer device will be positioned against the lesion area and shockwaves will be delivered at a gradually increasing energy, with a maximum energy level of 0.09mJ/mm2
Device: Extracorporeal Shockwave Therapy and debridement
Other: debridement and cleaning
Active Comparator: debridement and cleansing.
The standard treatment to the control group and the treatment group will be performed as an outpatient care procedure with no anesthesia. Patients will undergo wound debridement and cleansing. The physician will treat the patient in regard to his medical state: antibiotic medication if needed, dressing and off loading with Orthotic devices
Other: debridement and cleaning

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
To assess initial closure rate of the wound 4 weeks after the last treatment session, as compared to the control group receiving conventional standard of care.
Time Frame: four weeks
four weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hadassah Medical Organization

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2016

Primary Completion (Anticipated)

April 1, 2017

Study Registration Dates

First Submitted

January 31, 2016

First Submitted That Met QC Criteria

February 21, 2016

First Posted (Estimate)

February 25, 2016

Study Record Updates

Last Update Posted (Estimate)

February 25, 2016

Last Update Submitted That Met QC Criteria

February 21, 2016

Last Verified

January 1, 2016

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 0592-HMO-CTIL

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetic Foot Ulcers

Clinical Trials on Extracorporeal Shockwave Therapy and debridement

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe